May 7, 2026 04:05PM
Apr 27, 2026 04:06PM
Apr 27, 2026 04:05PM
Feb 19, 2026 04:05PM
Nov 6, 2025 04:05PM
Oct 1, 2025 04:51PM
Oct 1, 2025 04:45PM Prothena’s Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer’s Disease
Aug 27, 2025 04:05PM
Aug 27, 2025 04:05PM
Aug 27, 2025 04:05PM
Aug 4, 2025 04:05PM
May 8, 2025 04:05PM
Feb 20, 2025 04:05PM
Jan 29, 2025 09:12AM Cantor Fitzgerald provides update on Biotechnology stocks
Dec 16, 2024 04:55AM
Nov 12, 2024 04:05PM
Oct 1, 2024 06:05AM
Aug 8, 2024 04:05PM
May 28, 2024 04:06PM
May 28, 2024 04:05PM
May 8, 2024 04:05PM Prothena Reports First Quarter 2024 Financial Results and Business Highlights
Apr 15, 2024 04:06PM
Apr 15, 2024 04:05PM
Feb 15, 2024 04:05PM
Jan 8, 2024 08:30AM
Nov 2, 2023 04:05PM
Aug 3, 2023 04:05PM
Jun 27, 2023 04:05PM Prothena (PRTA) Announces Phase 3 VITAL Clinical Trial Results Published in Blood Showing Survival Benefit in Patients with Mayo Stage IV AL Amyloidosis Treated with Birtamimab
Jun 27, 2023 04:05PM
May 16, 2023 04:06PM
May 16, 2023 04:05PM
May 4, 2023 04:05PM
Apr 13, 2023 08:00AM
Feb 23, 2023 04:05PM
Dec 12, 2022 11:30AM Prothena (PRTA) Presents Data Demonstrating Consistent Survival Benefit Observed with Birtamimab in Mayo Stage IV AL Amyloidosis Patients in Phase 3 VITAL Study at ASH
Dec 12, 2022 11:30AM
Nov 3, 2022 09:05AM
Aug 8, 2022 04:05PM
Aug 8, 2022 04:05PM
May 5, 2022 04:05PM
May 5, 2022 04:05PM
Apr 26, 2022 08:30AM Prothena Corp. (PRTA) Granted FDA Fast Track Designation for PRX012
Apr 26, 2022 08:30AM
Apr 26, 2022 08:30AM
Mar 28, 2022 08:30AM
Mar 28, 2022 08:30AM
Mar 28, 2022 08:30AM
Feb 17, 2022 04:05PM
Feb 17, 2022 04:05PM Prothena Reports Fourth Quarter and Full Year 2021 Financial Results, and Provides Financial Guidance and Business Highlights
Sep 30, 2021 06:55AM

322,084 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All